ADMA
ADMA Biologics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
10.18
▲ 0.07 (0.69%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.11
Day high
10.35
Day low
9.98
Volume
2.10M
Market cap
$2.28B
P/E (TTM)
14.54
52W range
7.21 – 20.46
Trailing performance
Returnvs SPY
1W
+2.21%
+0.3%
1M
+5.82%
+4.7%
3M
+11.14%
+6.6%
6M
+9.94%
-8.2%
YTD
-44.19%
-58.4%
1Y
-30.56%
-47.0%
3Y
+184.36%
+102.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ADMA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.41M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | KOHLER TERRY Chief Financial Officer |
STOCK | 85.13K | $0 | Direct |
| May 27, 26 | GROSSMAN JERROLD B Director |
BUY | 6.40K | $50.62K | Direct |
| May 12, 26 | GROSSMAN JERROLD B Director |
BUY | 12.50K | $100.13K | Direct |
| May 11, 26 | GROSSMAN JERROLD B Director |
BUY | 12.50K | $100.13K | Direct |
| Mar 17, 26 | GUIHEEN LAWRENCE P Director |
STOCK | 30.00K | $0 | Direct |
| Mar 16, 26 | GROSSMAN ADAM S Chief Executive Officer |
CONVERSION | 15.00K | $81.00K | Direct |
| Mar 16, 26 | GROSSMAN ADAM S Chief Executive Officer |
SELL | 21.00K | $318.36K | Direct |
| Mar 13, 26 | GUIHEEN LAWRENCE P Director |
CONVERSION | 30.00K | $109.80K | Direct |
| Mar 9, 26 | KESTENBERG-MESSINA KAITLIN M. Officer |
CONVERSION | 10.10K | $32.33K | Direct |
| Mar 9, 26 | KESTENBERG-MESSINA KAITLIN M. Officer |
SELL | 10.10K | $157.80K | Direct |
| Mar 6, 26 | ELMS STEVEN A Director |
BUY | 14.00K | $217.42K | Indirect |
| Feb 17, 26 | GROSSMAN ADAM S Chief Executive Officer |
CONVERSION | 15.00K | $81.00K | Direct |
| Feb 17, 26 | GROSSMAN ADAM S Chief Executive Officer |
SELL | 21.00K | $337.68K | Direct |
| Feb 9, 26 | GROSSMAN JERROLD B Director |
STOCK | 10.69K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ELMS STEVEN A |
Director | — | Purchase |
FINGER ALISON CECILY |
Director | 45.62K | Stock Award(Grant) |
GROSSMAN ADAM S |
Chief Executive Officer | 3.84M | Conversion of Exercise of derivative security |
GROSSMAN JERROLD B |
Director | 612.99K | Purchase |
GUIHEEN LAWRENCE P |
Director | 186.51K | Stock Gift |
KESTENBERG-MESSINA KAITLIN M. |
Officer | 466.60K | Conversion of Exercise of derivative security |
KOHLER TERRY |
Chief Financial Officer | 143.15K | Stock Award(Grant) |
KWON YOUNG T. PH.D. |
Director | 263.02K | Stock Award(Grant) |
SALAS EDUARDO RENE |
Director | 21.58K | Stock Award(Grant) |
TADE BRAD L |
Chief Financial Officer | 261.66K | Stock Award(Grant) |
Fundamentals
Market cap$2.28B
Enterprise value$2.35B
Revenue (TTM)$512.28M
Gross profit$331.47M
EBITDA$224.19M
Net income$168.96M
EPS (TTM)$0.70
Free cash flow$54.76M
Total cash$136.02M
Total debt$203.84M
Book value / share$1.81
Shares outstanding223.98M
Float219.66M
Short % of float13.32%
Dividend yield0.00%
Beta (5Y)0.69
Valuation & profitability ratios
Trailing P/E14.54
Forward P/E10.79
PEG ratio—
Price / sales—
Price / book5.62
EV / revenue4.58
EV / EBITDA10.47
Gross margin64.70%
Operating margin42.16%
Profit margin32.98%
Return on equity41.90%
Return on assets21.78%
Debt / equity49.94
Current ratio6.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $510.17M | $426.45M | $258.21M | $154.08M | +19.6% |
| Operating revenue | $510.17M | $426.45M | $258.21M | $154.08M | +19.6% |
| Cost of revenue | $217.41M | $206.90M | $169.27M | $118.81M | +5.1% |
| Gross profit | $292.76M | $219.55M | $88.94M | $35.27M | +33.3% |
| Research & development | $4.76M | $1.81M | $3.30M | $3.61M | +162.7% |
| Selling, general & admin | $91.58M | $74.12M | $59.02M | $52.46M | +23.5% |
| Total operating expense | $101.32M | $80.57M | $67.31M | $74.63M | +25.8% |
| Operating income | $191.44M | $138.98M | $21.63M | -$39.37M | +37.7% |
| Net interest income | -$5.24M | -$11.83M | -$23.41M | -$19.23M | +55.7% |
| Pre-tax income | $182.66M | $125.71M | -$28.24M | -$65.90M | +45.3% |
| Tax provision | $35.73M | -$71.96M | $0 | $0 | +149.6% |
| Net income | $146.93M | $197.67M | -$28.24M | -$65.90M | -25.7% |
| Net income to common | $146.93M | $197.67M | -$28.24M | -$65.90M | -25.7% |
| Basic EPS | 0.62 | 0.85 | -0.13 | -0.33 | -27.1% |
| Diluted EPS | 0.60 | 0.81 | -0.13 | -0.33 | -25.9% |
| EBIT | $189.77M | $139.64M | -$3.21M | -$46.63M | +35.9% |
| EBITDA | $197.86M | $147.69M | $5.12M | -$39.51M | +34.0% |
| Basic shares | 238.30M | 233.08M | 223.98M | 197.87M | +2.2% |
| Diluted shares | 244.90M | 243.34M | 223.98M | 197.87M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $87.63M | $103.15M | $51.35M | $86.52M | -15.0% |
| Cash & short-term investments | $87.63M | $103.15M | $51.35M | $86.52M | -15.0% |
| Accounts receivable | $158.43M | $50.00M | $27.42M | $15.51M | +216.9% |
| Inventory | $206.47M | $170.24M | $172.91M | $163.28M | +21.3% |
| Total current assets | $466.51M | $331.41M | $257.01M | $270.40M | +40.8% |
| Property, plant & equipment | $71.71M | $63.34M | $63.47M | $68.75M | +13.2% |
| Goodwill & intangibles | $4.16M | $3.99M | $4.03M | $4.54M | +4.3% |
| Total assets | $624.24M | $488.68M | $329.18M | $348.46M | +27.7% |
| Total current liabilities | $69.54M | $55.54M | $49.81M | $39.27M | +25.2% |
| Current debt | $2.81M | — | — | — | — |
| Long-term debt | $69.33M | $72.34M | $130.59M | $142.83M | -4.2% |
| Total debt | $79.89M | $82.12M | $141.42M | $154.44M | -2.7% |
| Total liabilities | $146.92M | $139.66M | $193.98M | $196.49M | +5.2% |
| Retained earnings | -$161.65M | -$308.58M | -$506.26M | -$478.02M | +47.6% |
| Shareholder equity | $477.32M | $349.02M | $135.21M | $151.97M | +36.8% |
| Working capital | $396.97M | $275.87M | $207.21M | $231.13M | +43.9% |
| Net tangible assets | $473.16M | $345.03M | $131.18M | $147.43M | +37.1% |
| Shares issued | 239.79M | 236.62M | 226.06M | 221.82M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $146.93M | $197.67M | -$28.24M | -$65.90M | -25.7% |
| Depreciation & amortisation | $8.10M | $8.04M | $8.33M | $7.11M | +0.6% |
| Stock-based compensation | $20.03M | $13.62M | $6.19M | $5.21M | +47.1% |
| Change in working capital | -$139.59M | -$18.54M | -$10.12M | -$18.29M | -653.0% |
| Operating cash flow | $50.40M | $118.67M | $8.80M | -$59.51M | -57.5% |
| Capital expenditure | -$22.89M | -$8.57M | -$4.98M | -$13.91M | -167.0% |
| Investing cash flow | -$21.89M | -$8.57M | -$4.98M | -$13.91M | -155.3% |
| Share buybacks | -$31.94M | — | — | — | — |
| Financing cash flow | -$44.02M | -$58.30M | -$38.99M | $108.85M | +24.5% |
| Free cash flow | $27.50M | $110.10M | $3.82M | -$73.42M | -75.0% |
| End cash position | $87.63M | $103.15M | $51.35M | $86.52M | -15.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $124.39M | $114.49M | $139.16M | $134.22M | $121.98M | +8.6% |
| Operating revenue | $124.39M | $114.49M | $139.16M | $134.22M | $121.98M | +8.6% |
| Cost of revenue | $38.12M | $33.74M | $50.35M | $58.60M | $54.76M | +13.0% |
| Gross profit | $86.28M | $80.75M | $88.82M | $75.63M | $67.23M | +6.8% |
| Research & development | $6.01M | $2.60M | $1.38M | $1.53M | $1.03M | +131.6% |
| Selling, general & admin | $26.74M | $26.74M | $23.51M | $21.78M | $22.21M | -0.0% |
| Total operating expense | $33.83M | $30.46M | $26.07M | $24.61M | $24.43M | +11.1% |
| Operating income | $52.45M | $50.29M | $62.75M | $51.01M | $42.80M | +4.3% |
| Net interest income | -$2.19M | -$1.01M | -$1.14M | -$1.30M | -$1.43M | -117.1% |
| Pre-tax income | $50.24M | $57.13M | $61.59M | $47.52M | $40.10M | -12.1% |
| Tax provision | $12.41M | $11.80M | $12.22M | $11.09M | $5.88M | +5.2% |
| Net income | $37.82M | $45.33M | $49.38M | $36.43M | $34.22M | -16.6% |
| Net income to common | $37.82M | $45.33M | $49.38M | $36.43M | $34.22M | -16.6% |
| Basic EPS | 0.17 | 0.19 | 0.21 | 0.15 | 0.14 | -10.5% |
| Diluted EPS | 0.16 | 0.19 | 0.20 | 0.15 | 0.14 | -15.8% |
| EBIT | $53.66M | $59.23M | $63.22M | $49.19M | $41.93M | -9.4% |
| EBITDA | $55.44M | $61.07M | $65.27M | $51.21M | $43.99M | -9.2% |
| Basic shares | 228.23M | 236.07M | 237.97M | 238.60M | 241.49M | -3.3% |
| Diluted shares | 230.34M | 239.96M | 243.85M | 244.66M | 248.61M | -4.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $136.02M | $138.15M | $87.63M | $61.38M | $90.28M | -1.5% |
| Cash & short-term investments | $136.02M | $138.15M | $87.63M | $61.38M | $90.28M | -1.5% |
| Accounts receivable | $138.23M | $135.86M | $158.43M | $137.67M | $109.73M | +1.7% |
| Inventory | $239.31M | $222.10M | $206.47M | $196.67M | $191.46M | +7.8% |
| Total current assets | $528.20M | $511.17M | $466.51M | $402.65M | $399.56M | +3.3% |
| Property, plant & equipment | $72.81M | $71.41M | $71.71M | $78.78M | $66.46M | +2.0% |
| Goodwill & intangibles | $4.11M | $4.16M | $4.16M | $4.02M | $4.06M | -1.3% |
| Total assets | $684.21M | $665.18M | $624.24M | $568.69M | $558.38M | +2.9% |
| Total current liabilities | $75.76M | $73.54M | $69.54M | $56.49M | $74.94M | +3.0% |
| Current debt | $3.75M | $3.28M | $2.81M | $2.34M | — | +14.3% |
| Long-term debt | $192.84M | $193.58M | $69.33M | $70.08M | $73.40M | -0.4% |
| Total debt | $203.84M | $204.41M | $79.89M | $83.12M | $83.83M | -0.3% |
| Total liabilities | $276.00M | $274.86M | $146.92M | $137.50M | $160.06M | +0.4% |
| Retained earnings | -$78.50M | -$116.33M | -$161.65M | -$211.03M | -$247.46M | +32.5% |
| Shareholder equity | $408.21M | $390.32M | $477.32M | $431.19M | $398.32M | +4.6% |
| Working capital | $452.45M | $437.63M | $396.97M | $346.17M | $324.62M | +3.4% |
| Net tangible assets | $404.10M | $386.17M | $473.16M | $427.17M | $394.27M | +4.6% |
| Shares issued | 225.36M | 240.96M | 239.79M | 239.66M | 239.38M | -6.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $37.82M | $45.33M | $49.38M | $36.43M | $34.22M | -16.6% |
| Depreciation & amortisation | $1.78M | $1.84M | $2.05M | $2.02M | $2.06M | -3.2% |
| Stock-based compensation | $6.13M | $6.33M | $5.39M | $5.05M | $4.96M | -3.1% |
| Change in working capital | -$16.36M | $9.24M | -$22.52M | -$37.32M | -$23.00M | -277.0% |
| Operating cash flow | $29.54M | $58.25M | $35.64M | $13.29M | $21.14M | -49.3% |
| Capital expenditure | -$2.26M | -$2.60M | -$1.28M | -$14.37M | -$2.53M | +13.1% |
| Investing cash flow | -$2.26M | $2.40M | -$276.00K | -$14.37M | -$2.53M | -193.8% |
| Share buybacks | -$25.05M | -$130.19M | -$8.90M | -$23.04M | $0 | +80.8% |
| Financing cash flow | -$29.42M | -$10.13M | -$9.12M | -$27.82M | $48.00K | -190.4% |
| Free cash flow | $27.28M | $55.65M | $34.36M | -$1.07M | $18.61M | -51.0% |
| End cash position | $136.02M | $138.15M | $87.63M | $61.38M | $90.28M | -1.5% |
Options analytics
Put / call volume
0.60
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-90.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
169
Contracts, this expiry
Put volume
101
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
8.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.16 | 0.17 | +3.5% |
| Mar 2026 | 0.20 | 0.17 | -15.3% |
| Dec 2025 | 0.20 | 0.22 | +7.9% |
| Sep 2025 | 0.16 | 0.16 | +2.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.20 | 3 | $138.12M | +2.9% |
| Next quarter | 0.24 | 3 | $158.40M | +13.8% |
| Current year | 0.80 | 3 | $535.35M | +4.9% |
| Next year | 0.94 | 3 | $629.54M | +17.6% |
Analyst targets & ownership
Mean target$17.00
High target$21.00
Low target$12.00
Implied upside66.99%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders1.97%
Held by institutions92.76%
Institutions holding437
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.87
+3.19% from price
SMA 20
9.54
+6.74% from price
SMA 50
9.48
+7.43% from price
SMA 100
8.98
+13.43% from price
SMA 200
11.66
-12.70% from price
EMA 12
9.82
+3.64% from price
EMA 26
9.63
+5.67% from price
EMA 50
9.49
+7.30% from price
RSI (14)
60.5
Neutral
MACD (12,26,9)
0.19
Hist 0.07
ATR (14)
0.43
4.23% of price
Realised vol 30D
39.5%
Annualised
Bollinger upper
10.42
20, 2σ
Bollinger lower
8.66
20, 2σ
50 / 200 cross
Death
9.48 vs 11.66
Trend bias
Below 200
-12.70%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.80
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
39.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-62.7%
Peak to trough
Max drawdown 5Y
-69.0%
Peak to trough
ATR 14
0.43
4.23% of price
Beta (reported)
0.69
5Y monthly, from filing
Short interest
Shares short
24.21M
Prior 22.68M
Change vs prior
+6.7%
Shorts adding
% of float
13.32%
Elevated
% of shares out
10.81%
Against total outstanding
Days to cover
12.2
Crowded exit
Float
219.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 7, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 7, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Apr 21, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Apr 13, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 26, 26 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| May 8, 25 | Raymond James | MAINTAINED | Strong Buy | Strong Buy |
| Mar 4, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Nov 8, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 8, 24 | Raymond James | MAINTAINED | Strong Buy | Strong Buy |
| Oct 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 20, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-02
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEFA14A · 2026-04-15
Corporate Changes & Voting Matters
8-K · 2026-03-27
Corporate Changes & Voting Matters
8-K · 2026-03-02
Corporate Changes & Voting Matters
8-K · 2026-02-25
Headlines
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Zacks · 8d ago
ADMA Biologics (ADMA), Why Is It Back In The Spotlight?
Simply Wall St. · 10d ago
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Zacks · 13d ago
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Zacks · 13d ago
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Zacks · 18d ago
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks · 25d ago
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks · 26d ago
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Zacks · 29d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.